Genomic Characterization of Meningiomas

Meningiomas are the most common primary brain tumor in the US. Although the tumor suppressor gene NF2 is disrupted in approximately half of meningiomas, the complete spectrum of genetic changes in meningiomas remains poorly understood, particularly in the large subset of tumors without NF2 alterations. Therefore we performed whole-genome sequencing from 11 Grade I meningioma tumor-normal pairs and whole-exome sequencing from an additional 6 tumor-normal pairs to identify somatic mutations, insertions-deletions, copy-number alterations and rearrangements. We validated our results by performing focused sequencing across 48 additional meningiomas.]]> Partners HealthCare System Research Consent FormThis dataset contains data from a case set of 65 pairs of meningiomas and normal blood DNA, sequenced on Illumina HiSeq 2000. Of the 47 Grade I cases, 11 where sequenced by whole-genome methods, six were sequenced by whole-exome capture, and 30 were sequenced by OncoPanel, a custom target sequencing approach covering 645 cancer-related genes. An additional 15 Grade II and 3 Grade III tumor-normal pairs were sequenced by OncoPanel.- Histopathologic purity of ≥90%]]>